| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia | 58 | 2023 | 97 | 16.980 |
Why?
|
| Hematinics | 47 | 2023 | 49 | 15.330 |
Why?
|
| Renal Insufficiency, Chronic | 37 | 2023 | 97 | 14.400 |
Why?
|
| Erythropoietin | 42 | 2023 | 55 | 11.840 |
Why?
|
| Hemoglobins | 43 | 2023 | 81 | 7.500 |
Why?
|
| Kidney Diseases | 26 | 2019 | 115 | 6.930 |
Why?
|
| Renal Dialysis | 38 | 2023 | 113 | 6.900 |
Why?
|
| Kidney Failure, Chronic | 30 | 2019 | 161 | 6.350 |
Why?
|
| Tomography, X-Ray Computed | 26 | 2019 | 770 | 4.530 |
Why?
|
| Darbepoetin alfa | 19 | 2023 | 19 | 3.470 |
Why?
|
| Humans | 157 | 2023 | 29361 | 2.890 |
Why?
|
| Prolyl-Hydroxylase Inhibitors | 4 | 2022 | 4 | 2.680 |
Why?
|
| Epoetin Alfa | 19 | 2022 | 20 | 2.420 |
Why?
|
| Kidney | 11 | 2019 | 173 | 2.360 |
Why?
|
| Blast Injuries | 5 | 2016 | 7 | 2.250 |
Why?
|
| Barbiturates | 5 | 2023 | 9 | 1.990 |
Why?
|
| Middle Aged | 64 | 2022 | 9823 | 1.880 |
Why?
|
| Glycine | 3 | 2022 | 12 | 1.870 |
Why?
|
| Male | 79 | 2022 | 15637 | 1.780 |
Why?
|
| Female | 79 | 2023 | 16211 | 1.740 |
Why?
|
| Diabetes Mellitus, Type 2 | 10 | 2023 | 200 | 1.700 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2013 | 340 | 1.690 |
Why?
|
| Recombinant Proteins | 22 | 2022 | 251 | 1.630 |
Why?
|
| Cardiovascular Diseases | 16 | 2022 | 401 | 1.570 |
Why?
|
| Terrorism | 5 | 2016 | 13 | 1.430 |
Why?
|
| Iron | 7 | 2023 | 22 | 1.370 |
Why?
|
| Aged | 51 | 2022 | 9447 | 1.350 |
Why?
|
| Anemia, Iron-Deficiency | 4 | 2015 | 4 | 1.310 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2020 | 1220 | 1.280 |
Why?
|
| Adult | 40 | 2023 | 8604 | 1.240 |
Why?
|
| Nephrology | 4 | 2019 | 14 | 1.180 |
Why?
|
| Mass Screening | 3 | 2014 | 177 | 1.180 |
Why?
|
| Foreign Bodies | 3 | 2015 | 25 | 1.170 |
Why?
|
| Heart Failure | 10 | 2019 | 204 | 1.150 |
Why?
|
| Chronic Disease | 16 | 2010 | 495 | 1.080 |
Why?
|
| Risk Factors | 23 | 2020 | 2446 | 1.070 |
Why?
|
| Neoplasms | 3 | 2023 | 247 | 1.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2022 | 324 | 1.030 |
Why?
|
| Treatment Outcome | 25 | 2023 | 3476 | 1.000 |
Why?
|
| Lupus Nephritis | 4 | 2006 | 28 | 0.990 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 63 | 0.990 |
Why?
|
| Biopsy, Needle | 3 | 2012 | 101 | 0.990 |
Why?
|
| Diabetic Nephropathies | 5 | 2019 | 27 | 0.980 |
Why?
|
| Multiple Trauma | 4 | 2016 | 4 | 0.950 |
Why?
|
| Buprenorphine | 1 | 2023 | 5 | 0.940 |
Why?
|
| Benzhydryl Compounds | 1 | 2023 | 1 | 0.930 |
Why?
|
| Opioid-Related Disorders | 1 | 2023 | 49 | 0.870 |
Why?
|
| Liver Transplantation | 3 | 2015 | 79 | 0.840 |
Why?
|
| Bone Diseases, Metabolic | 3 | 2016 | 18 | 0.830 |
Why?
|
| Kidney Transplantation | 4 | 2009 | 125 | 0.820 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 4 | 2022 | 5 | 0.810 |
Why?
|
| Prevalence | 11 | 2018 | 491 | 0.810 |
Why?
|
| Endoscopy | 2 | 2015 | 181 | 0.800 |
Why?
|
| Vitamin D | 3 | 2013 | 32 | 0.790 |
Why?
|
| Farmers | 1 | 2020 | 1 | 0.780 |
Why?
|
| Colitis | 3 | 2005 | 37 | 0.780 |
Why?
|
| Occupational Exposure | 1 | 2020 | 25 | 0.770 |
Why?
|
| Metabolic Syndrome | 2 | 2013 | 66 | 0.750 |
Why?
|
| Prognosis | 9 | 2017 | 840 | 0.750 |
Why?
|
| Erythropoiesis | 4 | 2023 | 6 | 0.740 |
Why?
|
| United States Food and Drug Administration | 3 | 2010 | 70 | 0.740 |
Why?
|
| Myocardium | 1 | 2020 | 140 | 0.720 |
Why?
|
| Practice Guidelines as Topic | 7 | 2012 | 333 | 0.720 |
Why?
|
| Stroke | 9 | 2021 | 293 | 0.720 |
Why?
|
| Pandemics | 1 | 2022 | 236 | 0.710 |
Why?
|
| Retrospective Studies | 17 | 2023 | 3273 | 0.700 |
Why?
|
| Glomerular Filtration Rate | 8 | 2016 | 59 | 0.690 |
Why?
|
| Hypertension | 6 | 2018 | 266 | 0.680 |
Why?
|
| Myocardial Infarction | 5 | 2021 | 172 | 0.680 |
Why?
|
| Acute Kidney Injury | 3 | 2014 | 49 | 0.660 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2018 | 4 | 0.650 |
Why?
|
| Lower Extremity | 1 | 2018 | 38 | 0.640 |
Why?
|
| Ferric Compounds | 4 | 2015 | 6 | 0.630 |
Why?
|
| Risk Assessment | 12 | 2019 | 678 | 0.620 |
Why?
|
| Marijuana Smoking | 1 | 2017 | 5 | 0.610 |
Why?
|
| Head Injuries, Penetrating | 1 | 2017 | 1 | 0.600 |
Why?
|
| Wounds, Gunshot | 1 | 2017 | 3 | 0.600 |
Why?
|
| Boston | 6 | 2016 | 27 | 0.590 |
Why?
|
| Certification | 2 | 2019 | 49 | 0.590 |
Why?
|
| Ferritins | 5 | 2017 | 9 | 0.580 |
Why?
|
| Proteinuria | 4 | 2013 | 81 | 0.570 |
Why?
|
| Pathology | 1 | 2016 | 4 | 0.570 |
Why?
|
| Cytokines | 2 | 2008 | 348 | 0.570 |
Why?
|
| Contrast Media | 6 | 2019 | 125 | 0.570 |
Why?
|
| Evidence-Based Medicine | 4 | 2010 | 206 | 0.560 |
Why?
|
| Warfare | 1 | 2016 | 14 | 0.560 |
Why?
|
| Abdominal Injuries | 1 | 2015 | 4 | 0.550 |
Why?
|
| Biliary Fistula | 2 | 2006 | 5 | 0.550 |
Why?
|
| Triage | 1 | 2016 | 23 | 0.550 |
Why?
|
| Renal Replacement Therapy | 2 | 2015 | 24 | 0.550 |
Why?
|
| Bile Duct Neoplasms | 1 | 2015 | 12 | 0.540 |
Why?
|
| Cholangiocarcinoma | 1 | 2015 | 12 | 0.540 |
Why?
|
| Pelvis | 1 | 2015 | 30 | 0.540 |
Why?
|
| Societies, Medical | 2 | 2019 | 190 | 0.540 |
Why?
|
| Saudi Arabia | 6 | 2016 | 8 | 0.530 |
Why?
|
| Neck Injuries | 1 | 2015 | 3 | 0.530 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 79 | 0.530 |
Why?
|
| Craniocerebral Trauma | 1 | 2015 | 11 | 0.530 |
Why?
|
| Predictive Value of Tests | 8 | 2020 | 521 | 0.530 |
Why?
|
| Adolescent | 12 | 2016 | 2280 | 0.520 |
Why?
|
| Gastrostomy | 1 | 2015 | 8 | 0.520 |
Why?
|
| Jejunostomy | 1 | 2015 | 6 | 0.520 |
Why?
|
| Medicare | 4 | 2010 | 121 | 0.520 |
Why?
|
| Consanguinity | 2 | 2014 | 4 | 0.510 |
Why?
|
| Radiography, Interventional | 3 | 2012 | 24 | 0.500 |
Why?
|
| United States | 11 | 2017 | 2332 | 0.500 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 90 | 0.500 |
Why?
|
| Hypertension, Renal | 1 | 2014 | 3 | 0.490 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2014 | 20 | 0.480 |
Why?
|
| Acute Disease | 6 | 2017 | 226 | 0.480 |
Why?
|
| Ventricular Fibrillation | 1 | 2014 | 30 | 0.480 |
Why?
|
| India | 4 | 2020 | 21 | 0.470 |
Why?
|
| Cost of Illness | 1 | 2014 | 54 | 0.470 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 10 | 0.470 |
Why?
|
| Pediatrics | 1 | 2013 | 33 | 0.460 |
Why?
|
| Heart Arrest | 1 | 2014 | 58 | 0.450 |
Why?
|
| Biomedical Research | 1 | 2013 | 81 | 0.440 |
Why?
|
| Diagnosis, Differential | 9 | 2019 | 389 | 0.440 |
Why?
|
| Research Design | 4 | 2008 | 212 | 0.440 |
Why?
|
| Child | 8 | 2016 | 1345 | 0.440 |
Why?
|
| Kidney Tubules | 2 | 2009 | 10 | 0.430 |
Why?
|
| Platelet Activation | 1 | 2012 | 4 | 0.430 |
Why?
|
| Disease Outbreaks | 1 | 2012 | 88 | 0.430 |
Why?
|
| Splenic Diseases | 1 | 2012 | 3 | 0.430 |
Why?
|
| Tissue Donors | 3 | 2015 | 74 | 0.420 |
Why?
|
| Blood Platelets | 1 | 2012 | 49 | 0.420 |
Why?
|
| Spleen | 1 | 2012 | 51 | 0.420 |
Why?
|
| Intention to Treat Analysis | 2 | 2021 | 6 | 0.420 |
Why?
|
| Testis | 2 | 2018 | 11 | 0.420 |
Why?
|
| Abdomen, Acute | 3 | 2008 | 4 | 0.420 |
Why?
|
| Fanconi Syndrome | 1 | 2011 | 1 | 0.410 |
Why?
|
| Injections, Subcutaneous | 3 | 2010 | 32 | 0.410 |
Why?
|
| Red-Cell Aplasia, Pure | 2 | 2008 | 2 | 0.410 |
Why?
|
| Multiple Myeloma | 1 | 2011 | 30 | 0.400 |
Why?
|
| Mass Casualty Incidents | 3 | 2016 | 7 | 0.400 |
Why?
|
| Appendicitis | 2 | 2008 | 18 | 0.400 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2012 | 60 | 0.400 |
Why?
|
| Cross-Sectional Studies | 6 | 2020 | 965 | 0.400 |
Why?
|
| Bombs | 3 | 2015 | 3 | 0.390 |
Why?
|
| Liver | 2 | 2015 | 173 | 0.390 |
Why?
|
| Prospective Studies | 9 | 2022 | 1812 | 0.380 |
Why?
|
| Preoperative Care | 4 | 2015 | 135 | 0.380 |
Why?
|
| Drug Approval | 1 | 2010 | 30 | 0.370 |
Why?
|
| Biliary Tract Diseases | 1 | 2010 | 4 | 0.370 |
Why?
|
| Reimbursement Mechanisms | 1 | 2010 | 13 | 0.370 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2020 | 42 | 0.360 |
Why?
|
| Vascular Diseases | 1 | 2010 | 48 | 0.360 |
Why?
|
| Liver Diseases | 1 | 2010 | 41 | 0.350 |
Why?
|
| Aged, 80 and over | 11 | 2017 | 4851 | 0.350 |
Why?
|
| Early Diagnosis | 4 | 2014 | 65 | 0.350 |
Why?
|
| Calcium Compounds | 1 | 2009 | 2 | 0.350 |
Why?
|
| Minerals | 1 | 2009 | 6 | 0.350 |
Why?
|
| Bone Density Conservation Agents | 1 | 2009 | 14 | 0.340 |
Why?
|
| Kidney Glomerulus | 1 | 2009 | 54 | 0.340 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2009 | 44 | 0.340 |
Why?
|
| Needles | 1 | 2008 | 18 | 0.330 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2013 | 437 | 0.330 |
Why?
|
| Muscle Neoplasms | 1 | 2008 | 3 | 0.330 |
Why?
|
| Cost Savings | 1 | 2008 | 36 | 0.330 |
Why?
|
| Abdominal Muscles | 1 | 2008 | 7 | 0.330 |
Why?
|
| Pelvic Pain | 1 | 2008 | 12 | 0.330 |
Why?
|
| Hospital Mortality | 2 | 2014 | 141 | 0.330 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 61 | 0.330 |
Why?
|
| Phosphates | 1 | 2008 | 21 | 0.330 |
Why?
|
| Immunologic Factors | 1 | 2008 | 39 | 0.330 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 96 | 0.330 |
Why?
|
| Calculi | 1 | 2008 | 1 | 0.320 |
Why?
|
| Abdominal Abscess | 1 | 2008 | 2 | 0.320 |
Why?
|
| Nephritis, Interstitial | 2 | 2008 | 7 | 0.320 |
Why?
|
| Acute Coronary Syndrome | 1 | 2008 | 15 | 0.320 |
Why?
|
| Appendectomy | 1 | 2008 | 15 | 0.320 |
Why?
|
| Bone and Bones | 1 | 2009 | 125 | 0.320 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2008 | 35 | 0.320 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 2 | 2019 | 3 | 0.320 |
Why?
|
| Multicenter Studies as Topic | 2 | 2007 | 75 | 0.310 |
Why?
|
| Drainage | 3 | 2015 | 50 | 0.310 |
Why?
|
| Diabetic Angiopathies | 2 | 2019 | 8 | 0.310 |
Why?
|
| Age Factors | 4 | 2020 | 845 | 0.300 |
Why?
|
| Pancreatic Fistula | 1 | 2006 | 2 | 0.300 |
Why?
|
| Ascites | 1 | 2006 | 5 | 0.300 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2007 | 31 | 0.300 |
Why?
|
| Diabetes Complications | 1 | 2007 | 64 | 0.290 |
Why?
|
| Biopsy | 5 | 2019 | 234 | 0.290 |
Why?
|
| Algorithms | 4 | 2016 | 400 | 0.290 |
Why?
|
| Tissue and Organ Procurement | 1 | 2006 | 34 | 0.290 |
Why?
|
| Penile Neoplasms | 1 | 2005 | 2 | 0.280 |
Why?
|
| Inflammation | 1 | 2008 | 345 | 0.280 |
Why?
|
| Hernia, Abdominal | 1 | 2005 | 2 | 0.270 |
Why?
|
| Iron Compounds | 1 | 2005 | 2 | 0.260 |
Why?
|
| Metabolic Diseases | 1 | 2005 | 14 | 0.260 |
Why?
|
| Severity of Illness Index | 5 | 2012 | 1113 | 0.260 |
Why?
|
| Gallbladder Diseases | 1 | 2004 | 5 | 0.250 |
Why?
|
| Intestinal Fistula | 1 | 2004 | 7 | 0.250 |
Why?
|
| Colonic Diseases | 1 | 2004 | 12 | 0.250 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2004 | 27 | 0.250 |
Why?
|
| Immunosuppressive Agents | 2 | 2009 | 132 | 0.250 |
Why?
|
| Fertility | 1 | 2004 | 20 | 0.250 |
Why?
|
| Infertility | 1 | 2004 | 7 | 0.250 |
Why?
|
| Ovary | 1 | 2004 | 17 | 0.250 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 2004 | 4 | 0.250 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 55 | 0.250 |
Why?
|
| Omentum | 1 | 2004 | 8 | 0.250 |
Why?
|
| Cohort Studies | 7 | 2014 | 1939 | 0.250 |
Why?
|
| Glomerulonephritis | 1 | 2004 | 23 | 0.250 |
Why?
|
| Infarction | 1 | 2004 | 23 | 0.240 |
Why?
|
| Radiographic Image Enhancement | 1 | 2004 | 16 | 0.240 |
Why?
|
| Granuloma | 1 | 2003 | 13 | 0.240 |
Why?
|
| Ibuprofen | 1 | 2003 | 12 | 0.240 |
Why?
|
| Albuminuria | 1 | 2023 | 21 | 0.240 |
Why?
|
| Double-Blind Method | 8 | 2022 | 503 | 0.240 |
Why?
|
| Comorbidity | 3 | 2013 | 497 | 0.240 |
Why?
|
| Cholelithiasis | 1 | 2003 | 10 | 0.240 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2003 | 3 | 0.240 |
Why?
|
| Nurse's Role | 1 | 2005 | 118 | 0.240 |
Why?
|
| Opiate Substitution Treatment | 1 | 2023 | 2 | 0.240 |
Why?
|
| Incidence | 3 | 2017 | 756 | 0.230 |
Why?
|
| Narcotic Antagonists | 1 | 2023 | 14 | 0.230 |
Why?
|
| Glucosides | 1 | 2023 | 4 | 0.230 |
Why?
|
| Patient Education as Topic | 3 | 2010 | 162 | 0.230 |
Why?
|
| Hyperparathyroidism, Secondary | 2 | 2016 | 3 | 0.230 |
Why?
|
| Patients | 1 | 2023 | 31 | 0.230 |
Why?
|
| Catheter Ablation | 2 | 2015 | 78 | 0.230 |
Why?
|
| Survival Analysis | 3 | 2009 | 298 | 0.220 |
Why?
|
| Gastroenterology | 1 | 2022 | 11 | 0.220 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2004 | 89 | 0.220 |
Why?
|
| Colonic Polyps | 1 | 2022 | 23 | 0.220 |
Why?
|
| Young Adult | 5 | 2018 | 1935 | 0.210 |
Why?
|
| Survival Rate | 3 | 2014 | 349 | 0.210 |
Why?
|
| Data Collection | 1 | 2022 | 107 | 0.200 |
Why?
|
| Models, Biological | 1 | 2003 | 344 | 0.200 |
Why?
|
| Logistic Models | 2 | 2020 | 407 | 0.200 |
Why?
|
| Injections, Intravenous | 4 | 2008 | 56 | 0.200 |
Why?
|
| Tobacco, Smokeless | 1 | 2020 | 1 | 0.200 |
Why?
|
| Child, Preschool | 4 | 2016 | 641 | 0.200 |
Why?
|
| Confidence Intervals | 3 | 2012 | 96 | 0.190 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 215 | 0.190 |
Why?
|
| Disease Progression | 4 | 2017 | 788 | 0.190 |
Why?
|
| Quality of Life | 5 | 2023 | 664 | 0.190 |
Why?
|
| International Cooperation | 2 | 2019 | 32 | 0.190 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 78 | 0.180 |
Why?
|
| Time Factors | 5 | 2018 | 1618 | 0.180 |
Why?
|
| Pathologists | 1 | 2019 | 1 | 0.180 |
Why?
|
| Pathology, Clinical | 1 | 2019 | 3 | 0.180 |
Why?
|
| Mitochondrial Proteins | 1 | 2019 | 21 | 0.180 |
Why?
|
| Catheterization | 2 | 2012 | 51 | 0.180 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 55 | 0.180 |
Why?
|
| Hospitalization | 4 | 2017 | 317 | 0.180 |
Why?
|
| C-Reactive Protein | 2 | 2017 | 125 | 0.180 |
Why?
|
| Choledocholithiasis | 1 | 2019 | 2 | 0.180 |
Why?
|
| Administration, Oral | 1 | 2019 | 140 | 0.170 |
Why?
|
| Deglutition Disorders | 1 | 2019 | 45 | 0.170 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2002 | 202 | 0.170 |
Why?
|
| Myositis | 1 | 2019 | 23 | 0.170 |
Why?
|
| Running | 2 | 2016 | 10 | 0.170 |
Why?
|
| Hydroxamic Acids | 1 | 2018 | 5 | 0.170 |
Why?
|
| Metformin | 1 | 2019 | 21 | 0.170 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2018 | 9 | 0.170 |
Why?
|
| Metabolomics | 1 | 2018 | 23 | 0.170 |
Why?
|
| Ultrasonography, Interventional | 2 | 2012 | 63 | 0.170 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2018 | 1 | 0.170 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 61 | 0.170 |
Why?
|
| Fractures, Closed | 1 | 2018 | 2 | 0.170 |
Why?
|
| Foot Injuries | 1 | 2018 | 2 | 0.170 |
Why?
|
| Leiomyoma | 2 | 2008 | 10 | 0.160 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2018 | 10 | 0.160 |
Why?
|
| Radiation Injuries | 1 | 2018 | 34 | 0.160 |
Why?
|
| Ankle Injuries | 1 | 2018 | 12 | 0.160 |
Why?
|
| Health Literacy | 1 | 2020 | 102 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2010 | 194 | 0.160 |
Why?
|
| Up-Regulation | 2 | 2010 | 174 | 0.160 |
Why?
|
| Drug Costs | 2 | 2008 | 17 | 0.160 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2017 | 2 | 0.160 |
Why?
|
| Ultrasonography | 2 | 2018 | 226 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2010 | 132 | 0.160 |
Why?
|
| Sex Distribution | 2 | 2018 | 87 | 0.150 |
Why?
|
| Patient Selection | 2 | 2010 | 232 | 0.150 |
Why?
|
| Nephrologists | 1 | 2017 | 3 | 0.150 |
Why?
|
| Follow-Up Studies | 6 | 2014 | 1829 | 0.150 |
Why?
|
| Glasgow Coma Scale | 1 | 2017 | 12 | 0.150 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 85 | 0.150 |
Why?
|
| Sensitivity and Specificity | 5 | 2018 | 553 | 0.150 |
Why?
|
| Public Health | 1 | 2017 | 61 | 0.150 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 123 | 0.140 |
Why?
|
| Executive Function | 2 | 2014 | 121 | 0.140 |
Why?
|
| Blood Pressure | 1 | 2017 | 238 | 0.140 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 221 | 0.140 |
Why?
|
| Cognition Disorders | 2 | 2014 | 1010 | 0.140 |
Why?
|
| Muscle, Skeletal | 1 | 2019 | 349 | 0.140 |
Why?
|
| Pilot Projects | 3 | 2017 | 394 | 0.140 |
Why?
|
| Explosions | 1 | 2016 | 1 | 0.140 |
Why?
|
| Drug Monitoring | 2 | 2006 | 24 | 0.140 |
Why?
|
| Radiography | 1 | 2018 | 678 | 0.140 |
Why?
|
| Program Development | 1 | 2016 | 69 | 0.140 |
Why?
|
| Photochemotherapy | 1 | 2015 | 5 | 0.140 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2015 | 9 | 0.140 |
Why?
|
| Endosonography | 1 | 2015 | 11 | 0.140 |
Why?
|
| Diphosphates | 1 | 2015 | 1 | 0.140 |
Why?
|
| Dialysis Solutions | 1 | 2015 | 5 | 0.140 |
Why?
|
| Trauma Centers | 1 | 2015 | 7 | 0.130 |
Why?
|
| Radiopharmaceuticals | 2 | 2007 | 48 | 0.130 |
Why?
|
| Risk Reduction Behavior | 3 | 2011 | 54 | 0.130 |
Why?
|
| Endoscopy, Digestive System | 1 | 2015 | 9 | 0.130 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2014 | 8 | 0.130 |
Why?
|
| Curriculum | 1 | 2016 | 155 | 0.130 |
Why?
|
| Wounds, Penetrating | 1 | 2014 | 10 | 0.130 |
Why?
|
| Corneal Opacity | 1 | 2014 | 2 | 0.130 |
Why?
|
| Acidosis, Renal Tubular | 1 | 2014 | 2 | 0.130 |
Why?
|
| Enteral Nutrition | 1 | 2015 | 49 | 0.120 |
Why?
|
| Sex Factors | 2 | 2013 | 496 | 0.120 |
Why?
|
| Kidney Function Tests | 2 | 2017 | 21 | 0.120 |
Why?
|
| Electric Countershock | 1 | 2014 | 29 | 0.120 |
Why?
|
| Pedigree | 1 | 2013 | 77 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2012 | 162 | 0.120 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2014 | 19 | 0.120 |
Why?
|
| Coronary Angiography | 1 | 2014 | 91 | 0.120 |
Why?
|
| Diabetes Mellitus | 2 | 2018 | 137 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 145 | 0.120 |
Why?
|
| Blood Viscosity | 1 | 2013 | 3 | 0.120 |
Why?
|
| Defibrillators, Implantable | 1 | 2014 | 30 | 0.120 |
Why?
|
| Critical Care | 1 | 2016 | 234 | 0.110 |
Why?
|
| Age Distribution | 1 | 2013 | 94 | 0.110 |
Why?
|
| Middle East | 1 | 2012 | 5 | 0.110 |
Why?
|
| Electrocardiography | 1 | 2014 | 209 | 0.110 |
Why?
|
| Regression Analysis | 2 | 2012 | 298 | 0.110 |
Why?
|
| Calcinosis | 2 | 2014 | 47 | 0.110 |
Why?
|
| Animals | 3 | 2018 | 4577 | 0.110 |
Why?
|
| P-Selectin | 1 | 2012 | 3 | 0.110 |
Why?
|
| CD40 Ligand | 1 | 2012 | 8 | 0.110 |
Why?
|
| Splenic Artery | 1 | 2012 | 1 | 0.110 |
Why?
|
| Sclerosing Solutions | 1 | 2012 | 2 | 0.110 |
Why?
|
| Cell-Derived Microparticles | 1 | 2012 | 7 | 0.110 |
Why?
|
| Sclerotherapy | 1 | 2012 | 3 | 0.110 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2012 | 8 | 0.110 |
Why?
|
| Aneurysm, False | 1 | 2012 | 5 | 0.110 |
Why?
|
| Pneumothorax | 1 | 2012 | 10 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2012 | 116 | 0.100 |
Why?
|
| Spermatozoa | 2 | 2018 | 10 | 0.100 |
Why?
|
| Postoperative Hemorrhage | 1 | 2012 | 24 | 0.100 |
Why?
|
| Embolization, Therapeutic | 1 | 2012 | 26 | 0.100 |
Why?
|
| Thrombosis | 2 | 2017 | 59 | 0.100 |
Why?
|
| Microscopy, Electron | 1 | 2011 | 70 | 0.100 |
Why?
|
| Bone Marrow Transplantation | 1 | 2011 | 34 | 0.100 |
Why?
|
| Risk | 2 | 2010 | 217 | 0.100 |
Why?
|
| Drug Therapy, Combination | 3 | 2008 | 241 | 0.100 |
Why?
|
| Multivariate Analysis | 4 | 2015 | 324 | 0.100 |
Why?
|
| Hepatectomy | 1 | 2011 | 55 | 0.100 |
Why?
|
| Iron, Dietary | 1 | 2010 | 1 | 0.100 |
Why?
|
| Ferrosoferric Oxide | 1 | 2010 | 1 | 0.100 |
Why?
|
| Hepcidins | 1 | 2010 | 1 | 0.100 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2010 | 2 | 0.100 |
Why?
|
| Indicators and Reagents | 1 | 2010 | 14 | 0.100 |
Why?
|
| Awareness | 1 | 2010 | 37 | 0.100 |
Why?
|
| Cardiac Output | 1 | 2010 | 21 | 0.100 |
Why?
|
| Ethanol | 1 | 2012 | 134 | 0.090 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2010 | 6 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 391 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2011 | 638 | 0.090 |
Why?
|
| Consumer Product Safety | 1 | 2010 | 3 | 0.090 |
Why?
|
| Drug Labeling | 1 | 2010 | 6 | 0.090 |
Why?
|
| Erythrocytes | 1 | 2009 | 20 | 0.090 |
Why?
|
| Health Care Reform | 1 | 2010 | 20 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2010 | 227 | 0.090 |
Why?
|
| Developing Countries | 1 | 2009 | 22 | 0.090 |
Why?
|
| Truth Disclosure | 1 | 2009 | 8 | 0.090 |
Why?
|
| Calcium | 2 | 2016 | 495 | 0.090 |
Why?
|
| Hematocrit | 1 | 2009 | 11 | 0.090 |
Why?
|
| Global Health | 1 | 2009 | 55 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 218 | 0.090 |
Why?
|
| Parent-Child Relations | 1 | 2009 | 33 | 0.090 |
Why?
|
| Length of Stay | 2 | 2014 | 317 | 0.090 |
Why?
|
| Sirolimus | 1 | 2009 | 15 | 0.090 |
Why?
|
| Massachusetts | 1 | 2009 | 19 | 0.090 |
Why?
|
| Ergocalciferols | 1 | 2009 | 2 | 0.090 |
Why?
|
| Phosphorus | 1 | 2009 | 6 | 0.090 |
Why?
|
| Calcitriol | 1 | 2009 | 7 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2009 | 95 | 0.090 |
Why?
|
| Cilazapril | 1 | 2008 | 1 | 0.080 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2008 | 7 | 0.080 |
Why?
|
| Reference Values | 2 | 2013 | 227 | 0.080 |
Why?
|
| Ovarian Diseases | 1 | 2008 | 2 | 0.080 |
Why?
|
| Publication Bias | 1 | 2008 | 7 | 0.080 |
Why?
|
| Gadolinium | 1 | 2008 | 11 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2008 | 26 | 0.080 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2008 | 2 | 0.080 |
Why?
|
| Radiography, Abdominal | 1 | 2008 | 6 | 0.080 |
Why?
|
| Puerperal Disorders | 1 | 2008 | 8 | 0.080 |
Why?
|
| Menorrhagia | 1 | 2008 | 4 | 0.080 |
Why?
|
| Leuprolide | 1 | 2008 | 7 | 0.080 |
Why?
|
| Probability | 1 | 2008 | 94 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2008 | 13 | 0.080 |
Why?
|
| Medicaid | 1 | 2008 | 37 | 0.080 |
Why?
|
| Prednisone | 1 | 2008 | 67 | 0.080 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2008 | 18 | 0.080 |
Why?
|
| Interleukin-8 | 1 | 2008 | 32 | 0.080 |
Why?
|
| Polycythemia | 1 | 2008 | 1 | 0.080 |
Why?
|
| Fournier Gangrene | 1 | 2008 | 2 | 0.080 |
Why?
|
| Nephrectomy | 1 | 2008 | 29 | 0.080 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2008 | 15 | 0.080 |
Why?
|
| Sclerosis | 1 | 2008 | 68 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2009 | 285 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2010 | 230 | 0.080 |
Why?
|
| Hypoglycemia | 1 | 2008 | 14 | 0.080 |
Why?
|
| Iatrogenic Disease | 1 | 2008 | 26 | 0.080 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2008 | 19 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2008 | 76 | 0.080 |
Why?
|
| Metabolic Clearance Rate | 1 | 2007 | 10 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2008 | 108 | 0.080 |
Why?
|
| Half-Life | 1 | 2007 | 18 | 0.080 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2008 | 47 | 0.080 |
Why?
|
| Biological Availability | 1 | 2007 | 26 | 0.080 |
Why?
|
| Pregnancy Complications | 1 | 2008 | 52 | 0.080 |
Why?
|
| Periodicals as Topic | 1 | 2008 | 41 | 0.080 |
Why?
|
| Primary Prevention | 1 | 2008 | 38 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2008 | 100 | 0.080 |
Why?
|
| Hematopoiesis | 1 | 2007 | 11 | 0.080 |
Why?
|
| Caregivers | 1 | 2009 | 143 | 0.080 |
Why?
|
| Cardiac Catheterization | 1 | 2008 | 88 | 0.080 |
Why?
|
| Diffusion of Innovation | 1 | 2007 | 38 | 0.080 |
Why?
|
| Organotechnetium Compounds | 1 | 2007 | 8 | 0.080 |
Why?
|
| Ciprofloxacin | 1 | 2007 | 29 | 0.080 |
Why?
|
| Patient Dropouts | 1 | 2007 | 27 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 215 | 0.080 |
Why?
|
| Transplantation, Homologous | 1 | 2008 | 277 | 0.070 |
Why?
|
| Tuberculosis | 1 | 2007 | 25 | 0.070 |
Why?
|
| Cause of Death | 2 | 2019 | 65 | 0.070 |
Why?
|
| Bone Diseases | 1 | 2007 | 24 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 402 | 0.070 |
Why?
|
| Pregnancy | 1 | 2008 | 404 | 0.070 |
Why?
|
| Bias | 1 | 2006 | 33 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 340 | 0.070 |
Why?
|
| Morbidity | 1 | 2006 | 63 | 0.070 |
Why?
|
| Laparoscopy | 1 | 2008 | 145 | 0.070 |
Why?
|
| Fluoroscopy | 1 | 2006 | 52 | 0.070 |
Why?
|
| Mortality | 2 | 2019 | 86 | 0.070 |
Why?
|
| Inpatients | 1 | 2008 | 141 | 0.070 |
Why?
|
| Catheters, Indwelling | 1 | 2006 | 25 | 0.070 |
Why?
|
| Graft Survival | 1 | 2006 | 98 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2009 | 1184 | 0.070 |
Why?
|
| Cadaver | 1 | 2006 | 359 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2012 | 957 | 0.070 |
Why?
|
| Causality | 1 | 2005 | 53 | 0.060 |
Why?
|
| Histology | 1 | 2004 | 3 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 76 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 56 | 0.060 |
Why?
|
| Penis | 1 | 2005 | 67 | 0.060 |
Why?
|
| Patient Care Planning | 1 | 2005 | 56 | 0.060 |
Why?
|
| Biomarkers | 1 | 2008 | 692 | 0.060 |
Why?
|
| Melena | 1 | 2004 | 1 | 0.060 |
Why?
|
| Ovum | 1 | 2004 | 4 | 0.060 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2004 | 4 | 0.060 |
Why?
|
| Embryo, Mammalian | 1 | 2004 | 31 | 0.060 |
Why?
|
| Oocytes | 1 | 2004 | 16 | 0.060 |
Why?
|
| Cell Transplantation | 1 | 2004 | 29 | 0.060 |
Why?
|
| Cryopreservation | 1 | 2004 | 24 | 0.060 |
Why?
|
| Nephritis | 1 | 2003 | 1 | 0.060 |
Why?
|
| Nephrosis | 1 | 2003 | 4 | 0.060 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2003 | 1 | 0.060 |
Why?
|
| Iothalamic Acid | 1 | 2003 | 2 | 0.060 |
Why?
|
| Iodine Radioisotopes | 1 | 2003 | 16 | 0.060 |
Why?
|
| Crohn Disease | 1 | 2004 | 46 | 0.060 |
Why?
|
| Syndrome | 1 | 2003 | 82 | 0.060 |
Why?
|
| Colitis, Ulcerative | 1 | 2004 | 66 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2022 | 10 | 0.060 |
Why?
|
| Nucleosomes | 1 | 2002 | 3 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2022 | 51 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2022 | 50 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2003 | 288 | 0.050 |
Why?
|
| Memory | 2 | 2014 | 318 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2002 | 100 | 0.050 |
Why?
|
| Apoptosis | 1 | 2002 | 251 | 0.050 |
Why?
|
| Rural Population | 1 | 2020 | 23 | 0.050 |
Why?
|
| Myoglobinuria | 1 | 2019 | 2 | 0.040 |
Why?
|
| Carotid Artery, Internal | 1 | 2019 | 11 | 0.040 |
Why?
|
| Rhabdomyolysis | 1 | 2019 | 5 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2019 | 30 | 0.040 |
Why?
|
| Education, Distance | 1 | 2019 | 18 | 0.040 |
Why?
|
| Muscle Weakness | 1 | 2019 | 32 | 0.040 |
Why?
|
| Creatinine | 2 | 2009 | 44 | 0.040 |
Why?
|
| Sperm Motility | 1 | 2018 | 5 | 0.040 |
Why?
|
| Myocardial Revascularization | 1 | 2018 | 18 | 0.040 |
Why?
|
| Mental Health | 1 | 2020 | 105 | 0.040 |
Why?
|
| Organ Size | 1 | 2018 | 107 | 0.040 |
Why?
|
| Cardiovascular Agents | 1 | 2018 | 28 | 0.040 |
Why?
|
| Cerebral Infarction | 1 | 2019 | 152 | 0.040 |
Why?
|
| Age of Onset | 1 | 2018 | 108 | 0.040 |
Why?
|
| Veins | 1 | 2017 | 8 | 0.040 |
Why?
|
| Systole | 1 | 2017 | 18 | 0.040 |
Why?
|
| Thrombolytic Therapy | 1 | 2018 | 56 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2017 | 7 | 0.040 |
Why?
|
| Arteries | 1 | 2017 | 17 | 0.040 |
Why?
|
| Hypotension | 1 | 2017 | 27 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2017 | 34 | 0.040 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2017 | 24 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 1442 | 0.040 |
Why?
|
| Transferrin | 2 | 2008 | 6 | 0.040 |
Why?
|
| Body Weight | 1 | 2017 | 133 | 0.040 |
Why?
|
| Smoking | 1 | 2018 | 194 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 432 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2016 | 9 | 0.030 |
Why?
|
| Parathyroid Hormone | 1 | 2016 | 24 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2015 | 57 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 29 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 27 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2015 | 30 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2015 | 53 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2015 | 118 | 0.030 |
Why?
|
| Triglycerides | 1 | 2015 | 41 | 0.030 |
Why?
|
| Oliguria | 1 | 2014 | 1 | 0.030 |
Why?
|
| Burns, Chemical | 1 | 2014 | 2 | 0.030 |
Why?
|
| Diuretics | 1 | 2014 | 15 | 0.030 |
Why?
|
| Sodium-Bicarbonate Symporters | 1 | 2014 | 1 | 0.030 |
Why?
|
| Basal Ganglia Diseases | 1 | 2014 | 11 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2014 | 12 | 0.030 |
Why?
|
| Hypoxia | 1 | 2014 | 60 | 0.030 |
Why?
|
| Homozygote | 1 | 2014 | 23 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2015 | 222 | 0.030 |
Why?
|
| Mice | 1 | 2018 | 1620 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 107 | 0.030 |
Why?
|
| Recurrence | 1 | 2014 | 350 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 26 | 0.030 |
Why?
|
| Sepsis | 1 | 2014 | 144 | 0.030 |
Why?
|
| Infant | 1 | 2014 | 531 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2013 | 113 | 0.030 |
Why?
|
| Hemoglobinometry | 1 | 2012 | 1 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 254 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 37 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2012 | 321 | 0.030 |
Why?
|
| Thailand | 1 | 2009 | 11 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2009 | 130 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 1251 | 0.020 |
Why?
|
| Disease Management | 1 | 2009 | 114 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2008 | 67 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2007 | 19 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2007 | 56 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2007 | 33 | 0.020 |
Why?
|
| Osteomyelitis | 1 | 2007 | 22 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2006 | 51 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 36 | 0.020 |
Why?
|
| Demography | 1 | 2006 | 77 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2006 | 75 | 0.020 |
Why?
|